NanoGroup S.A. has finalized the strategic acquisition of 100% of the shares in DOTO MEDICAL sp. z o.o. and full rights to the innovative aptamer platform from PURE BIOLOGICS S.A.. This is a key step that significantly strengthens NanoGroup’s R&D potential in the area of innovative medical technologies.

The transaction, valued at PLN 800,000, includes the acquisition:

1. 100% of shares in DOTO MEDICAL sp. z o.o.

1. Receivables from a loan granted to DOTO MEDICAL sp. z o.o. by PURE BIOLOGICS S.A. in the principal amount of PLN 626,000, with contractual interest of 10% per annum and repayment due by December 31, 2026.

1. Rights to three key patents:

• PL239946 (national patent – Poland)

• EP3350195B1 (European patent)

• US10450673B2 (US patent).

 

All acquired patents cover the same innovative method: synthesis and purification of modified nucleotides using a click chemistry (Huisgen azide-alkyne cycloaddition) reaction. The acquisition of ownership of patent rights and claims means that NanoGroup, through DOTO Medical, has full scientific and commercial disposition of the aptamer platform and is free of any encumbrances to third parties.
The patents expire between 2035 and 2036.

The acquired patents form the foundation of a high-tech platform for identifying chemically modified DNA aptamers. By combining SELEX technology with a set of modified nucleotides, it is possible to obtain molecules with high affinity, selectivity and enzymatic resistance.

Potential applications for this innovative technology are broad and include:

• Modern therapies with improved targeting mechanisms.

• Advanced biosensors with increased sensitivity.

• Biological treatment technologies, such as as filter components.

The transaction is a strategic element in NanoGroup’s development, particularly in the area of end-stage renal failure, a disease that leads to the need for permanent dialysis or transplantation. In the short term, the acquired technology will find application in a system being developed by NanoGroup for perfusion and storage of organs for transplantation. It will serve as an innovative method of purifying perfusion fluid from inflammatory factors (cytokines), which is expected to significantly improve the quality and safety of stored organs.

The acquisition also lays the foundation for further commercialization of the aptamer technology platform for other applications in the global market. The company plans to develop solutions in areas such as nephrology (through further development of filtration to support dialysis at DOTO MEDICAL sp. z o.o.) and oncology (through the development of targeting systems for anti-cancer therapies being developed at NanoGroup S.A.).